Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a shareholder lawsuit that ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Dividend stocks are a great one-two punch, offering a steady stream of income as well as the potential for share appreciation. Finding the best dividend stocks is much easier said than done, however.

Dyne Therapeutics Inc. 4.43% $1.38B ...

After hours: January 31 at 4:03:08 PM EST Loading Chart for TCRX ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on GERN stock, giving a Buy rating yesterday.Invest with ...

Sanofi S.A. Part Cert-1.97% €8.03M ...